European Drug Utilization Study
European Drug Utilization Study
The purpose of this retrospective observational study is to evaluate the characteristics of
 patients receiving Seroquel XR as treatment for their Major Depressive Disorder. The study
 will also investigate how the medication is used for these patients and if there are any
 differences in drug utilisation between the included countries. The study is observing
 patients initiating Seroquel XR during a 9 month period corresponding to 3 to 12 months
 following the launch of the product in each country for the MDD indication. A drug
 utilisation questionnaire will be used to collect study data from patients' medical records.
A Multinational, Multicenter, Retrospective, Observational Drug Utilisation Study of Seroquel
 Extended Release (XR) Prescribed by Psychiatrists as Treatment for Major Depressive Disorder
 (MDD) in Selected Countries in the European Union (EU)
Inclusion Criteria:

 -  Provision of informed consent before initiation of any collection of questionnaire
 data.

 -  Documented clinical diagnosis of Major Depressive Disorder, Single Episode, or
 Recurrent.

 -  Initiation of Seroquel XR for treatment of MDD during the period defining the
 inception cohort, i.e. from 3 months after launch until the index date (12 months
 after launch).

 Exclusion Criteria:

 -  If participating in any clinical trial during the time from 3 months after launch
 until the index date, the patient cannot take part in this study.